News & Updates

A phase II study has demonstrated the safety of faecal microbiota transplantation (FMT) in patients with cirrhosis treated with lactulose and rifaximin, with no related adverse events (AEs) seen. FMT also results in lower rates of hepatic encephalopathy (HE) recurrence.

The use of the injectable extended-release naltrexone for alcohol use disorder in patients with advanced alcohol-associated liver disease (ALD) does not appear to carry a substantial hepatotoxicity or liver decompensation risk, according to a study.

A recent study has provided data bolstering the current recommendation of using carvedilol to prevent a first decompensation of cirrhosis in patients with compensated cirrhosis.

Metabolic burden in patients with chronic hepatitis B (CHB) and concurrent steatotic liver disease (SLD) may exacerbate the risks of all-cause, liver-related, and cardiovascular mortality, suggests a study.

Long-term treatment with odevixibat led to sustained improvements in pruritus scores and reductions in serum bile acid (sBA) levels among patients with Alagille syndrome (ALGS), based on a pooled analysis of the phase III ASSERT and ASSERT-EXT studies presented at ESPGHAN 2025.

Cyanoacrylate (CYA) injection delivers better results when augmented with endoscopic ultrasonography (EUS)-guided coil embolization for gastric variceal obliteration in a single-centre study.